All News
Filter News
Found 808,606 articles
-
Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.
-
North Carolina-based vTv Therapeutics revealed some potential hope for Alzheimer’s patients from its Phase III azeliragon study despite the drug failing to meet primary endpoints in April.
-
As the Brexit deadline looms closer and closer there are numerous critical questions as to how the move will impact the landscape of pharmaceutical industries across the U.K., Europe and potentially the United States.
-
Some accelerators come out of government and academic institutions, while others have specific big pharma backing. Many use a combination of all of the above, while some are private in nature linked to venture capital firms. Let’s look at some of the accelerators linked to big pharma.
-
Training the next generation of scientists is a key for the future of the biotech industry and Regeneron Pharmaceuticals is taking a lead in that responsibility through its sponsorship of the Regeneron Science Talent Search.
-
15 Ways to be Happy at Work
5/10/2018
Some studies show that over half of all Americans are not happy with their jobs. What can be the reasons? How to be happy at work? Find solutions here. -
Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting
5/10/2018
Twenty abstracts including eight oral presentations to showcase Jazz's breadth and depth of sleep medicine innovation [10-May-2018] Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting Twenty abstracts including eight oral pre
-
ATTUNE Knee System Linked to Improvements in Patient Quality of Life and Reduced Length of Hospital Stay
5/10/2018
Recent Evidence Shows Potential Positive Impact of Implant Design on Functional Outcomes and Hospital Discharge Status [10-May-2018] ATTUNE Knee System Linked to Improvements in Patient Quality of Life and Reduced Length of Hospital Stay Recent Evidence Shows
-
Faxitron VisionCT System Granted 510(k) Clearance for True 3D Imaging of Breast Specimens
5/10/2018
First-ever CT system cleared by the FDA for enhanced intraoperative margin assessment of biopsies and lumpectomies.
-
GenomeDx Biosciences' Genomic Data Featured at 2018 AUA Conference in Multiple Prostate and Bladder Cancer Presentations
5/10/2018
-- Presentations Highlight Versatility of Decipher Tests and Decipher GRID Technology Platform --
-
Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results
5/10/2018
Core Businesses Driving Strong Financial Performance CRINONE® Revenues Increased 30% and Juniper Pharma Services (JPS) Revenues Increased 55% Year-over-Year Conference Call at 8:30 a.m. EDT Today
-
Valeant To Seek Refinancing of its Existing Credit Agreement
5/10/2018
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it is seeking to amend and restate its existing credit agreement (the "Credit Agreement") and borrow $3.815 billion of new Term B loans (the "New Term B Loans") under the Credit Agreement
-
Lynparza (olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer
5/10/2018
AstraZeneca today announced that Health Canada has approved Lynparza® (olaparib) tablets, as a monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting
-
ReShape Lifesciences Announces Submission for Approval of ReShape Balloon™ in Canada
5/10/2018
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the submission of an application to the Medical Devices Bureau of the Therapeutic Products Directorate in Canada that seeks to amend the Company's existing Canadian medical device license to include distribution of the Company's current generation ReShape Balloon™ and associated accessories.
-
MiMedx To Participate In The Bank of America Merrill Lynch Healthcare Conference On May 16, 2018
5/10/2018
MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, announced today that it will participate in the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, Nevada.
-
Motus GI to Present Data at Digestive Disease Week® 2018 Showing Pure-Vu® System May Reduce Costs and Incidence of Colorectal Cancer
5/10/2018
May 10, 2018 12:05 UTC Motus GI to Present Data at Digestive Disease Week® 2018 Showing Pure-Vu® System May Reduce Costs and Incidence of Colorectal Cancer FORT LAUDERDALE, Fla.--( BUSINESS WIRE )-- Motus GI Holdings, Inc. , (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that data related to the Company’s Pure-Vu® System will
-
Veracyte to Launch New Afirma Xpression Atlas and Present Platform Performance Data at AACE 2018 Meeting
5/10/2018
Multiple Abstracts Showcasing “Real-World” Performance of the Afirma Genomic Sequencing Classifier also to be Presented
-
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
5/10/2018
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer, will present at the following investor conferences
-
Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2018 Health Care Conference and the UBS Global Healthcare Conference
5/10/2018
Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care instruments and consumables for the medical and veterinary markets worldwide, announced today that management will present at the following investor conferences
-
Aravive Biologics Achieves Proof-of-Mechanism for Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500, in Ongoing Phase 1 Trial
5/10/2018
Objective of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics for AVB-S6-500